As of January 22, 2025, Mersana Therapeutics (MRSN) has a market cap of $65.164 million USD. According to our data, Mersana Therapeutics is ranked No.8000 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $65.16 M |
-63.11%
|
Dec 31, 2024 | $0.18 B |
-38.36%
|
Dec 29, 2023 | $0.29 B |
-60.41%
|
Dec 30, 2022 | $0.72 B |
-5.79%
|
Dec 31, 2021 | $0.77 B |
-76.63%
|
Dec 31, 2020 | $3.29 B |
364.40%
|
Dec 31, 2019 | $0.71 B |
40.44%
|
Dec 31, 2018 | $0.50 B |
-75.17%
|
Dec 29, 2017 | $2.03 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
ADC Therapeutics
ADCT
|
$0.16 B |
-0.000 M
|
Switzerland
|
Sutro Biopharma
STRO
|
$0.16 B |
-0.000 M
|
USA
|
Zymeworks
ZYME
|
$1.01 B |
-0.000 M
|
Canada
|
BioAtla
BCAB
|
$28.93 M |
0.000 M
|
USA
|
Avidity Biosciences
RNA
|
$3.59 B |
-0.000 M
|
USA
|
Nektar Therapeutics
NKTR
|
$0.17 B |
0.000 M
|
USA
|
CytomX Therapeutics
CTMX
|
$65.57 M |
0.000 M
|
USA
|
Xencor
XNCR
|
$1.45 B |
0.000 M
|
USA
|
Pieris Pharmaceuticals
PIRS
|
$17.96 M |
0.000 M
|
USA
|
Market Cap | = | MRSN Stock Price | * | MRSN Shares Outstanding |
= | $0.53 | * | 0.12 B | |
= | $65.16 M |